Compare AbCellera Biologics Inc (ABCL) vs ASML Holding NV (ASML) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs ASML Holding NV — how do they compare? AbCellera Biologics Inc trades at $7.19 (market cap $2.35B), while ASML Holding NV trades at $1,741.09 (market cap $662.67B). The key difference: ASML Holding NV is far larger — about 282× AbCellera Biologics Inc's market cap, and ASML Holding NV pays a 0.5% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | ASML | |
|---|---|---|
Market Cap | $2.35B | $662.67B |
Sector | Health | Technology |
52-Week High | $8.12 | $1.99K |
52-Week Low | $2.78 | $689.63 |
Enterprise Value | $1.99B | $656.21B |
Dividend Yield | — | 0.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
ASML trades at $1,747.28, down 1.25% amid semiconductor sector volatility. The stock shows strong fundamentals with 2025 revenue of $32.67B and net income of $9.61B, supported by robust profitability margins. Technical indicators are neutral, with support near $1,748. Recent news highlights AI-driven demand and geopolitical risks in chip supply chains.
Outlook remains positive given ASML's monopoly in EUV lithography and analyst consensus price target of $2,210. Risks include cyclical semiconductor demand and geopolitical tensions. Earnings beat in Q1 2026 reinforces growth trajectory, but high valuations require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About ASML Holding NV
Founded in 1984 and based in the Netherlands, ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photomask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a meaningful portion of the cost of making cutting-edge chips. Chipmakers require next-generation EUV lithography tools from ASML to continue past the 5-nanometer process node. ASML's products are used at every major semiconductor manufacturer, including Intel, Samsung, and TSMC.
Read more on ASML →
